Hims Between Novo Lawsuit Risk and CEO Stock Sale
Reading Time: 3 minutes
Novo Nordisk intensifies action against suppliers of Wegovy copies. CEO sells a stock package worth over $30 million. The US telemedicine company Hims & Hers Health (HIMS) has long been more than just a digital healthcare player for investors. With the addition of personalized ("compounded”) versions of the weight-loss drug Wegovy to its product line, Hims has catapulted itself into the billion-dollar GLP-1 market – and into the sights of Novo Nordisk. Legal tug-of-war over "compounded” Wegovy Novo Nordisk is conducting...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
